CN113747902A - 具有从视网膜细胞去除脂褐素的活性的物质的组合物 - Google Patents

具有从视网膜细胞去除脂褐素的活性的物质的组合物 Download PDF

Info

Publication number
CN113747902A
CN113747902A CN202080031946.8A CN202080031946A CN113747902A CN 113747902 A CN113747902 A CN 113747902A CN 202080031946 A CN202080031946 A CN 202080031946A CN 113747902 A CN113747902 A CN 113747902A
Authority
CN
China
Prior art keywords
cyclodextrin
pharmaceutically acceptable
lipofuscin
sbe
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080031946.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·M·诺恰里
E·R·布伦南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CN113747902A publication Critical patent/CN113747902A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080031946.8A 2019-03-05 2020-03-03 具有从视网膜细胞去除脂褐素的活性的物质的组合物 Pending CN113747902A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814028P 2019-03-05 2019-03-05
US62/814,028 2019-03-05
PCT/US2020/020805 WO2020180872A1 (en) 2019-03-05 2020-03-03 Compositions of matter with activity to remove lipofuscin from retinal cells

Publications (1)

Publication Number Publication Date
CN113747902A true CN113747902A (zh) 2021-12-03

Family

ID=72337111

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080031946.8A Pending CN113747902A (zh) 2019-03-05 2020-03-03 具有从视网膜细胞去除脂褐素的活性的物质的组合物

Country Status (16)

Country Link
US (1) US20220118002A1 (https=)
EP (1) EP3934660A4 (https=)
JP (1) JP7573881B2 (https=)
KR (1) KR20210142651A (https=)
CN (1) CN113747902A (https=)
AU (1) AU2020232266A1 (https=)
BR (1) BR112021017529A2 (https=)
CA (1) CA3132466A1 (https=)
CO (1) CO2021012267A2 (https=)
EA (1) EA202192183A1 (https=)
IL (1) IL286002A (https=)
MX (1) MX2021010650A (https=)
PH (1) PH12021552131A1 (https=)
SG (1) SG11202109541YA (https=)
WO (1) WO2020180872A1 (https=)
ZA (1) ZA202106559B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116253809A (zh) * 2023-04-19 2023-06-13 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3205822A1 (en) * 2021-01-22 2022-07-28 Marcelo M. NOCIARI Compositions and methods for the identification of compounds that protect against lipofuscin cytotoxicity
AU2023420130A1 (en) * 2022-12-30 2025-08-14 Cornell University Acid cyclodextrins for the treatment of lipofuscin buildups and ocular diseases
WO2025147228A1 (en) * 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. Treatment for asymptomatic stargardt disease patients with gildeuretinol acetate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012100142A2 (en) * 2011-01-20 2012-07-26 Cornell University Treatments for retinal disorders
US20120302601A1 (en) * 2009-12-11 2012-11-29 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CN104540506A (zh) * 2012-08-17 2015-04-22 Pharmaking株式会社 包含s-烯丙基-l-半胱氨酸作为有效成分的眼病预防或治疗用组合物及包含它的医药制剂
WO2018091859A1 (en) * 2016-11-18 2018-05-24 Warneford Healthcare Limited Ophthalmic compositions comprising a cyclodextrin as sole active agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US8679511B2 (en) * 2009-10-01 2014-03-25 Duquesne University of the Holy Spririt In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
WO2014152959A1 (en) * 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2016168772A1 (en) 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120302601A1 (en) * 2009-12-11 2012-11-29 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2012100142A2 (en) * 2011-01-20 2012-07-26 Cornell University Treatments for retinal disorders
CN104540506A (zh) * 2012-08-17 2015-04-22 Pharmaking株式会社 包含s-烯丙基-l-半胱氨酸作为有效成分的眼病预防或治疗用组合物及包含它的医药制剂
WO2018091859A1 (en) * 2016-11-18 2018-05-24 Warneford Healthcare Limited Ophthalmic compositions comprising a cyclodextrin as sole active agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116253809A (zh) * 2023-04-19 2023-06-13 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法
CN116253809B (zh) * 2023-04-19 2024-11-05 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法

Also Published As

Publication number Publication date
EP3934660A4 (en) 2022-11-23
JP7573881B2 (ja) 2024-10-28
WO2020180872A1 (en) 2020-09-10
CA3132466A1 (en) 2020-09-10
PH12021552131A1 (en) 2022-08-22
KR20210142651A (ko) 2021-11-25
US20220118002A1 (en) 2022-04-21
EP3934660A1 (en) 2022-01-12
EA202192183A1 (ru) 2022-01-14
ZA202106559B (en) 2025-01-29
IL286002A (en) 2021-10-31
JP2022525007A (ja) 2022-05-11
AU2020232266A1 (en) 2021-09-23
SG11202109541YA (en) 2021-09-29
BR112021017529A2 (pt) 2021-11-09
MX2021010650A (es) 2021-12-10
CO2021012267A2 (es) 2021-10-20

Similar Documents

Publication Publication Date Title
US10849922B2 (en) Treatments for retinal disorders
JP7573881B2 (ja) 網膜細胞からリポフスチンを除去する活性を有する組成物
US12036190B2 (en) Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
EP3368088B1 (en) Compositions and methods for treatment of peroxisomal disorders and leukodystrophies
AU2008240138B2 (en) Treatment of Gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
JP2022033749A (ja) Ｅｒｔナイーブ患者及びｅｒｔ経験患者におけるファブリー病の処置
HK1242998A1 (zh) 治疗法布里病的给药方案
JP6837835B2 (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
US12157779B2 (en) Cyclodextrin dimers, compositions thereof, and uses thereof
JP2018530592A (ja) 代謝性ミオパチーの治療に使用するためのｓｇｌｔ−２阻害剤
RU2428189C2 (ru) Применение производных холест-4-ен-3-она для получения цитопротекторного лекарственного средства
Li et al. Bioinspired fine-tuning of the mechanical rigidity of SNEDDS for the efficient crossing of multiple gastrointestinal barriers
EP1912658B1 (en) Therapeutic protocols using hyaluronan
Zhang et al. Size dependent effects of Gold Nanoparticles in ISO-induced Hyperthyroid Rats
US20240082221A1 (en) Compositions and methods for the identification of compounds that protect against lipofuscin cytotoxicity
Liu et al. A shear-responsive nanosystem engineered from fucoidan targets endothelial for atherosclerosis therapy
Sun et al. S-allyl cysteine protects retinal pigment epithelium cells from hydroquinone-induced apoptosis through mitigating cellular response to oxidative stress.
US9283243B2 (en) CD36 inhibition to control obesity and insulin sensitivity
US10821086B2 (en) Muscular atrophy-inducing agent using hypometabolism-inducing substance T1AM, and use thereof in treating muscular hypertrophy
US11186603B2 (en) Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses
Zhang et al. Pterostilbene protects against doxorubicin-induced cardiotoxicity in canines via a gut microbiota–6AN–NOX2 axis
Yang et al. An injectable hyaluronic acid hydrogel protects against retinal pigment epithelial injury induced by sodium iodate
Song et al. Dual-targeted and ROS-responsive dexamethasone prodrug liposomes for enhanced therapy of acute lung injury
Hussein The journey of Sotagliflozin: from its status as a withdrawn candidate for the treatment of diabetes mellitus, to its repurposing as a groundbreaking drug for the management of heart failure.
KR20230175183A (ko) 화합물을 표적화하는 리소좀-관련 막 단백질 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211203